United States, January 31, 2025-- TruNeb has unveiled upgrades to its portable nebulizer, elevating its role in supporting individuals managing respiratory conditions such as asthma and COPD.

Ultrafine Mist: Our rechargeable nebulizer uses advanced ultrasonic mesh technology to transform liquids into fine mist particles. Two Adjustable Modes: Featuring two modes, the Strong Mode ...

The powerful Inspiration Elite is the newest and lightest compressor nebulizer system in the Respironics family is here. It's durable, easy to use and easy to maintain. But best of all ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions ...

The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

Barbara Obstoj-Cardwell is the Managing Editor of The Pharma Letter, which in 2010 acquired the archives of The Pharma Marketletter, a publication that Barbara owned since 1991 and prior to that ...